Format

Send to

Choose Destination

RETRACTED ARTICLE

See: Retraction Notice

Nutr J. 2015 Jan 10;14:5. doi: 10.1186/1475-2891-14-5.

Impact of weight loss diet associated with flaxseed on inflammatory markers in men with cardiovascular risk factors: a clinical study.

Author information

1
Department of Medicine, Division of Medical Nutrition, Ribeirão Preto Medical School, University of São Paulo, Avenida Bandeirantes, 3900 Bairro Monte Alegre, CEP: 14049-900, Ribeirão Preto, São Paulo, Brazil. priscilafassini@usp.br.

Abstract

BACKGROUND:

Flaxseed has received attention for its anti-inflammatory and antioxidant role. The present study hypothesizes if flaxseed added to a weight loss diet could improve the lipid and metabolic profiles and decrease risk factors related to cardiovascular disease.

METHODS:

In a prospective, single blinded 42 days protocol, subjects were allocated into two groups with low carbohydrates intake: GriceLC (35% of carbohydrate and 60g of raw rice powder per day) and GflaxLC (32% of carbohydrate and 60g of flaxseed powder per day). Blood pressure, anthropometric measures and serum levels of isoprostane, C-reactive protein, Tumor Necrosis Factor-alpha, glucose, lipidic profile, uric acid, adiponectin, leptin and insulin were measured at baseline and at the end of interventions. Serum and urinary enterodiol and enterolactione were also measured.

RESULTS:

A total of 27 men with cardiovascular risk factors were evaluated, with mean age of 33 ± 10 years to GriceLC and 40 ± 9 years to GflaxLC. Both groups experienced weight loss and systolic blood pressure reduction. A decrease in inflammatory markers (CRP and TNF-α) was observed after flaxseed intake (mean decrease of 25% and 46% for GflaxLC respectively). All groups also showed improvement in levels of total cholesterol, LDL-c, uric acid and adiponectin. Only GflaxLC group showed a decrease in triglyceride levels.

CONCLUSION:

This study suggests that flaxseed added to a weight loss diet could be an important nutritional strategy to reduce inflammation markers such as CRP and TNF-α.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT02132728.

PMID:
25577201
PMCID:
PMC4326402
DOI:
10.1186/1475-2891-14-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center